High Dose Chemotherapy Followed By PBSC Rescue for HD

Hodgkin Disease Clinical Trial

Official title:

Use of High Dose Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Relapsed or Resistant Hodgkin's Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00186251
• Other study ID #: BMT24
• Secondary ID: BMT2413322
• Status: Completed
• Phase: N/A
• First received: September 13, 2005
• Last updated: November 9, 2012
• Start date: March 1998
• Est. completion date: July 2005

Study information

• Verified date: July 2012
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

To evaluate the role of high dose chemotherapy with autologous hematopoietic cell transplantation in the treatment of Hodgkin's Disease.

Description:

Use of High Dose Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Relapsed or Resistant Hodgkin's Disease

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: July 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 70 Years

Eligibility

Inclusion Criteria:- adequate organ function

• recurrent HD Exclusion Criteria:- CNS disease

• no prior malignancy

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hodgkin Disease

Intervention

Procedure:
• high dose chemo then auto hematopoietic cell transplant

Locations

Country	Name	City	State
United States	Stanford University School of Medicine	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival
Primary	FFS
Primary	Response rates
Secondary	Toxicity of high dose chemotherapy